APP下载

重组人血管内皮抑制素联合培美曲塞加奈达铂方案治疗晚期肺腺癌的效果观察

2017-12-14王敏赵建华

中国当代医药 2017年32期

王敏 赵建华

[摘要]目的 观察重组人血管内皮抑制素联合培美曲塞加奈达铂方案治疗晚期肺腺癌的效果。方法 选取2015年3月~2017年1月我院接诊的64例晚期肺腺癌患者。将患者按照入院先后顺序分为研究组(32例)和对照组(32例)。对照组应用培美曲塞加奈达铂进行治疗,研究组在对照组基础上应用重组人血管内皮抑制素进行治疗。两个疗程后,比较两组患者的治疗效果和不良反应发生情况。结果 研究组患者治疗的总有效率为84.38%,明显高于对照组的56.25%(P<0.05)。两组血红蛋白下降,恶心、呕吐的不良反应发生情况差异有统计学意义(P<0.05);白细胞下降、乏力的不良反应发生情况差异无统计学意义(P>0.05)。结论 重组人血管内皮抑制素联合培美曲塞加奈达铂治疗晚期肺腺癌的方法具有高效、不良反应少的优点。

[关键词]重组人血管内皮抑制素;培美曲塞;奈达铂;肺腺癌

[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2017)11(b)-0061-03

[Abstract]Objective To observe the effect of Recombinant Human Endostatin combined with Pemetrexed plusing Nadeplatin regimen advanced lung adenocarcinoma.Methods From March 2015 to January 2017,64 patients with advanced lung adenocarcinoma treated in our hospital were selected.The patients were divided into the study group (32 cases) and control group (32 cases) according to the admission order.The control group was treated with Pemetrexed combined with Nadeplatin,while the study group was treated with Recombinant Human EndostatinRecombinant Human Endostatin on the basis of the control group.After 2 courses of treatment,the treatment effect and incidence of adverse reactions in patients between the two groups were compared.Results The total effective rate of treatment was 84.38% in the study group,which was significantly higher than that in the control group (56.25%) (P<0.05).There was a significant difference in the incidence of adverse reactions of hemoglobin descent,nausea and vomiting between the two groups (P<0.05),while there was no significant difference of white blood cell decline,fatigue between the two group (P>0.05).Conclusion The method of Recombinant Human Endostatin combined with Pemetrexed plusing Nadeplatin in the treatment of advanced lung adenocarcinoma has the advantages of high efficiency and less adverse reaction.

[Key words]Recombinant Human Endostatin;Pemetrexed;Nadeplatin;Lung adenocarcinoma

近几年,由于环境污染加重和吸烟人数增多,肺癌发生率日渐增高,已經成为致死率第一的癌症[1]。其中,非小细胞肺癌(non-small-cell carcinoma,NSCLC)占80%左右,肺腺癌占NSCLC的50%以上[2]。肺腺癌诊断时多处于分级的Ⅲ~Ⅳ期,属于晚期。治疗的首选方法是药物化疗,但是效果依然不够明显。由于多数患者为老年人,故在化疗过后的毒副作用非常多,给患者带来了诸多不适;若降低药物用量,则达不到理想的效果。本研究主要探讨重组人血管内皮抑制素联合培美曲塞加奈达铂方案治疗晚期肺腺癌的效果,现报道如下。

1资料与方法

1.1一般资料

选取2015年3月~2017年1月我院接诊的64例晚期肺腺癌患者,将其随机分为研究组、对照组,每组32例。患者均知情同意本研究并签署知情同意书。……

登录APP查看全文